Fulcrum Therapeutics (FULC) Set to Announce Earnings on Monday

Fulcrum Therapeutics (NASDAQ:FULC) will post its quarterly earnings results before the market opens on Monday, May 13th. Analysts expect Fulcrum Therapeutics to post earnings of ($0.44) per share for the quarter.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its quarterly earnings results on Tuesday, February 27th. The company reported ($0.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.04. Fulcrum Therapeutics had a negative return on equity of 36.65% and a negative net margin of 3,470.05%. The company had revenue of $0.87 million for the quarter, compared to the consensus estimate of $0.65 million. On average, analysts expect Fulcrum Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Fulcrum Therapeutics Stock Down 1.0 %

Shares of Fulcrum Therapeutics stock traded down $0.08 during trading on Tuesday, reaching $7.67. 100,712 shares of the company were exchanged, compared to its average volume of 610,850. Fulcrum Therapeutics has a twelve month low of $2.65 and a twelve month high of $13.70. The business has a 50-day moving average price of $9.05 and a 200-day moving average price of $7.15. The firm has a market capitalization of $476.69 million, a price-to-earnings ratio of -4.91 and a beta of 2.35.

Wall Street Analyst Weigh In

FULC has been the topic of a number of analyst reports. HC Wainwright increased their price target on shares of Fulcrum Therapeutics from $14.00 to $17.00 and gave the company a “buy” rating in a research report on Wednesday, February 28th. Royal Bank of Canada began coverage on shares of Fulcrum Therapeutics in a report on Wednesday, March 13th. They issued an “outperform” rating and a $14.00 price target for the company. The Goldman Sachs Group boosted their target price on Fulcrum Therapeutics from $5.00 to $6.00 and gave the company a “neutral” rating in a research note on Thursday, January 25th. Finally, Piper Sandler lifted their price objective on Fulcrum Therapeutics from $13.00 to $15.00 and gave the company an “overweight” rating in a report on Wednesday, February 28th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $13.17.

Insider Activity

In related news, VP Greg Tourangeau sold 4,884 shares of the stock in a transaction on Friday, March 8th. The shares were sold at an average price of $11.72, for a total transaction of $57,240.48. Following the completion of the transaction, the vice president now owns 11,807 shares in the company, valued at $138,378.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 4.10% of the stock is owned by corporate insiders.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.